We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




High Risk HPV Multiplex Assay Clinically Validated

By LabMedica International staff writers
Posted on 04 Apr 2016
Persistent infection with at least one of the high-risk carcinogenic human papillomavirus (HPV) types is the primary risk factor for the development of cervical cancer and HPV is found in virtually all cases of cervical cancer and precursor lesions.

Providing clear information about infected HPV genotypes in the stage of infection, clearance, and persistence is important to manage patient monitoring and treatment; however, conventional cytology tests do not determine HPV infection, but detect only cytological abnormality.

Scientists at the Catholic University of Korea (Seoul, Republic of Korea) collected 1,137specimens from Korean women that were randomly selected from the liquid-based cervical specimens between January and June 2014. More...
All specimens were collected with a cytobrush, and were placed in a Huro Path liquid-based cytology sampling device (CelltraZone; Seoul, Republic of Korea). They were stored at -70 °C until HPV testing. Each specimen was divided into two aliquots and then used for HPV detection tests. The cervical cytological examination was performed by experienced cytopathologists.

The investigators used the Anyplex II HPV HR detection kit (Seegene Inc.; Seoul, Republic of Korea) which is a new, multiplex, real-time polymerase chain reaction assay to detect individual 14 high-risk (HR) human papillomavirus (HPV) types in a single tube. For each sample, HPV detection and genotyping were performed using a CFX96 real-time thermocycler (Bio-Rad; Hercules, CA, USA). They compared the assay with the Hybrid Capture 2 (Qiagen; Valencia, CA) using the non-inferiority score test in a routine cervical cancer screening setting. The intra laboratory and inter laboratory agreements of HPV HR were also evaluated.

The scientists found that overall agreement between the two assays was 92.4% (1,051 of 1,137) with a κ value of 0.787. Clinical sensitivity of HPV HR for high-grade squamous intraepithelial lesions and cervical intraepithelial lesions grade 2 or worse was 94.4% and 92.5%, respectively. The respective values for Hybrid Capture 2 were 93.1% and 87.5%. Clinical sensitivity and specificity of HPV HR were not inferior to those of Hybrid Capture 2. The HPV HR showed good intra laboratory and inter laboratory reproducibility at 98.0% and 97.4% respectively.

The authors concluded that their data indicate that the HPV HR assay was highly comparable to HC2 for clinical equivalence and reproducibility based on international guidelines. The individual typing information for 14 hrHPV genotypes, including HPV-16 and HPV-18, provided by the HPV HR can be an important tool in patient management. The study was published in the March 2016 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

Catholic University of Korea
CelltraZone 
Bio-Rad



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
HPV Test
Allplex HPV28 Detection
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.